The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Curis; Jounce Therapeutics
Stock and Other Ownership Interests - Jounce Therapeutics
Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
 
Howard A. Burris
No Relationships to Disclose
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Bayer Schering Pharma (Inst); Bicycle Therapeutics (Inst); Blend Therapeutics (Inst); Boehringer Ingelheim (Inst); Celator (Inst); Elekta (Inst); Endocyte (Inst); Genmab (Inst); Heron (Inst); Ignyta (Inst); Janssen (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Upsher-Smith (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); TaiRx, Inc. (Inst)
 
Shivaani Kummar
Consulting or Advisory Role - Corvus Pharmaceuticals; MedTree (I)
Research Funding - Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Loxo (Inst); Pfizer (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Tesaro; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Russell Kent Pachynski
Consulting or Advisory Role - Argos Therapeutics; Bavarian Nordic; Dendreon
Speakers' Bureau - Dendreon; Genentech/Roche; Genomic Health; Merck
Research Funding - Ferring
 
Scott S. Tykodi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Calithera Biosciences; Prometheus
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Prometheus (Inst)
 
Geoffrey Thomas Gibney
Consulting or Advisory Role - Novartis
Speakers' Bureau - Merck
 
Tanguy Y. Seiwert
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Innate Pharma; Jounce Therapeutics; Lilly; Merck; Merck Serono
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech; Loxo; Novartis; Theravance
Research Funding - Adaptimmune; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech; Merck; Novartis
Travel, Accommodations, Expenses - Affymetrix
 
Patricia LoRusso
Leadership - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech/Roche; Novartis
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; Astellas Pharma; Astex Pharmaceuticals; Boehringer Ingelheim; Genentech; Novartis; Pfizer
Speakers' Bureau - Genentech
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
James Hilbert
Employment - Applied BioMath; Boehringer Ingelheim; Genzyme (I)
Stock and Other Ownership Interests - Pfizer
 
Josh F Apgar
No Relationships to Disclose
 
Fei Hua
Employment - Pfizer
 
John M Burke
No Relationships to Disclose
 
Manny Lazaro
Employment - Forum Pharmaceuticals; Jounce Therapeutics
Stock and Other Ownership Interests - Jounce Therapeutics
 
Myles Clancy
No Relationships to Disclose
 
Baoyu Ding
Employment - Jounce Therapeutics; Vertex
Stock and Other Ownership Interests - Jounce Therapeutics
 
Elizabeth G. Trehu
Employment - Jounce Therapeutics; Promedior
Leadership - Jounce Therapeutics; Promedior
Stock and Other Ownership Interests - Jounce Therapeutics; Promedior
 
Timothy Anthony Yap
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
Research Funding - AstraZeneca; Clearbridge Biomedics; Vertex
Patents, Royalties, Other Intellectual Property - Employee of The Institute of Cancer Research, which has a financial interest in the discovery and development of anticancer drugs (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Vertex